{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:32:15Z","timestamp":1792078335221,"version":"4.4.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"am","delay-in-days":292,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ajem.2024.01.010","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T01:20:55Z","timestamp":1705800055000},"page":"89-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["GLP-1 agonists: A review for emergency clinicians"],"prefix":"10.1016","volume":"78","author":[{"given":"Brit","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Koyfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Bridwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2024.01.010_bb0005","author":"Centers for Disease Control and Prevention"},{"issue":"2","key":"10.1016\/j.ajem.2024.01.010_bb0010","first-page":"142","article-title":"The epidemic of obesity and diabetes: trends and treatments","volume":"38","author":"Barnes","year":"2011","journal-title":"Tex Heart Inst J"},{"issue":"3","key":"10.1016\/j.ajem.2024.01.010_bb0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr"},{"issue":"5","key":"10.1016\/j.ajem.2024.01.010_bb0020","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.clinthera.2011.04.024","article-title":"Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment","volume":"33","author":"Neumiller","year":"2011","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.ajem.2024.01.010_bb0025","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11892-013-0377-9","article-title":"The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists","volume":"13","author":"Eckerle Mize","year":"2013","journal-title":"Curr Diab Rep"},{"issue":"4","key":"10.1016\/j.ajem.2024.01.010_bb0030","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.ajem.2024.01.010_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000705","article-title":"Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands","volume":"7","author":"Hunt","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"10.1016\/j.ajem.2024.01.010_bb0040","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/obr.12465","article-title":"Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity","volume":"18","author":"Burcelin","year":"2017","journal-title":"Obes Rev"},{"issue":"12","key":"10.1016\/j.ajem.2024.01.010_bb0045","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jdiacomp.2017.08.005","article-title":"A comprehensive review of the FDA-approved labels of diabetes drugs: indications, safety, and emerging cardiovascular safety data","volume":"31","author":"Gourgari","year":"2017","journal-title":"J Diabetes Complicat"},{"issue":"8","key":"10.1016\/j.ajem.2024.01.010_bb0050","first-page":"560","article-title":"Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice","volume":"47","author":"Sauer","year":"2015","journal-title":"Horm Metab Res"},{"issue":"15 Suppl","key":"10.1016\/j.ajem.2024.01.010_bb0055","first-page":"S297","article-title":"Semaglutide 2.4-mg injection as a novel approach for chronic weight management","volume":"28","author":"Kyrillos","year":"2022","journal-title":"Am J Manag Care"},{"issue":"344","key":"10.1016\/j.ajem.2024.01.010_bb0060","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"10","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ajem.2024.01.010_bb0065","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in adults with overweight or obesity","volume":"384","author":"JPH","year":"2021","journal-title":"N Engl J Med"},{"issue":"10278","key":"10.1016\/j.ajem.2024.01.010_bb0070","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ajem.2024.01.010_bb0075","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous Semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ajem.2024.01.010_bb0080","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ajem.2024.01.010_bb0085","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ajem.2024.01.010_bb0090","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"issue":"3 Suppl","key":"10.1016\/j.ajem.2024.01.010_bb0095","doi-asserted-by":"crossref","first-page":"33B","DOI":"10.1016\/j.amjcard.2011.03.046","article-title":"Cardiovascular effects of glucagonlike peptide-1 agonists","volume":"108","author":"Davidson","year":"2011","journal-title":"Am J Cardiol"},{"issue":"Suppl. 2","key":"10.1016\/j.ajem.2024.01.010_bb0100","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.2337\/dc11-s231","article-title":"Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability","volume":"34","author":"Garber","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajem.2024.01.010_bb0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-642-17214-4_3","article-title":"GLP-1 agonists and dipeptidyl-peptidase IV inhibitors","volume":"203","author":"Gallwitz","year":"2011","journal-title":"Handb Exp Pharmacol"},{"issue":"15","key":"10.1016\/j.ajem.2024.01.010_bb0110","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ajem.2024.01.010_bb0115","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1530\/EJE-09-0101","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"160","author":"Monami","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.ajem.2024.01.010_bb0120","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/dom.12251","article-title":"The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems","volume":"16","author":"Seufert","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.ajem.2024.01.010_bb0125","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajem.2024.01.010_bb0130","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"5","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"issue":"3\u20134","key":"10.1016\/j.ajem.2024.01.010_bb0135","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"issue":"13","key":"10.1016\/j.ajem.2024.01.010_bb0140","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"7","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.ajem.2024.01.010_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.ajem.2024.01.010_bb0155","author":"Ozempic"},{"key":"10.1016\/j.ajem.2024.01.010_bb0160","author":"Weygovy"},{"key":"10.1016\/j.ajem.2024.01.010_bb0165","author":"RYBELSUS"},{"key":"10.1016\/j.ajem.2024.01.010_bb0170","author":"Saxenda"},{"key":"10.1016\/j.ajem.2024.01.010_bb0175","author":"Victoza"},{"key":"10.1016\/j.ajem.2024.01.010_bb0180","author":"Mounjaro"},{"key":"10.1016\/j.ajem.2024.01.010_bb0185","author":"Trulicity"},{"issue":"Spec Feature","key":"10.1016\/j.ajem.2024.01.010_bb0190","first-page":"126","article-title":"Tanzeum (Albiglutide): a once-weekly GLP-1 receptor agonist subcutaneous injection approved for the treatment of patients with type 2 diabetes","volume":"8","author":"Fala","year":"2015","journal-title":"Am Health Drug Benefits"},{"issue":"4","key":"10.1016\/j.ajem.2024.01.010_bb0195","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.ajem.2024.01.010_bb0200","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology."},{"issue":"5","key":"10.1016\/j.ajem.2024.01.010_bb0205","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1345\/aph.1M676","article-title":"Association of pancreatitis with glucagon-like peptide-1 agonist use","volume":"44","author":"Anderson","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ajem.2024.01.010_bb0210","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy","year":"2015","journal-title":"Drugs Context"},{"issue":"1","key":"10.1016\/j.ajem.2024.01.010_bb0215","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ajem.2024.01.010_bb0220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/dia.2014.0188","article-title":"Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"17","author":"Sun","year":"2015","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"10.1016\/j.ajem.2024.01.010_bb0225","article-title":"Glucagon-like peptide analogues for type 2 diabetes mellitus","volume":"2011","author":"Shyangdan","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.ajem.2024.01.010_bb0230","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/MPA.0b013e31824e67a3","article-title":"Exenatide- induced chronic damage of pancreatic tissue in rats","volume":"41","author":"Yu","year":"2012","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.ajem.2024.01.010_bb0235","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4158\/EP11290.OR","article-title":"Elevated amylase and lipase levels in patients using glucagon-like peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting","volume":"18","author":"Lando","year":"2012","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.ajem.2024.01.010_bb0240","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/MPA.0000000000000229","article-title":"LEADER 3-lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER trial","volume":"43","author":"Steinberg","year":"2014","journal-title":"Pancreas"},{"issue":"5","key":"10.1016\/j.ajem.2024.01.010_bb0245","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.apsb.2023.02.020","article-title":"A potentially serious adverse effect of GLP-1 receptor agonists","volume":"13","author":"Lu","year":"2023","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"10.1016\/j.ajem.2024.01.010_bb0250","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.ajem.2024.01.010_bb0255","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","article-title":"Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus","volume":"176","author":"Faillie","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.ajem.2024.01.010_bb0260","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40262-017-0528-2","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment","volume":"56","author":"Marbury","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.ajem.2024.01.010_bb0265","doi-asserted-by":"crossref","first-page":"332","DOI":"10.18176\/jiaci.0274","article-title":"Anaphylaxis to long-acting release exenatide","volume":"28","author":"Ornelas","year":"2018","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"10.1016\/j.ajem.2024.01.010_bb0270","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jaip.2014.05.011","article-title":"A case report of allergy to exenatide","volume":"2","author":"P\u00e9rez","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.ajem.2024.01.010_bb0275","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2213-8587(19)30382-1","article-title":"Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis","volume":"8","author":"Pradhan","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.ajem.2024.01.010_bb0280","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.2337\/dc19-0720","article-title":"Allergic reaction to exenatide and lixisenatide but not to liraglutide: unveiling anaphylaxis to glucagon-like peptide 1 receptor agonists","volume":"42","author":"Shamriz","year":"2019","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ajem.2024.01.010_bb0285","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jdiacomp.2012.05.018","article-title":"Vesiculopustular dermatosis: an uncommon side-effect of liraglutide?","volume":"26","author":"Besemer","year":"2012","journal-title":"J Diabetes Complicat"},{"issue":"6","key":"10.1016\/j.ajem.2024.01.010_bb0290","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1684\/ejd.2019.3691","article-title":"An unusual case of a generalised cutaneous drug reaction to liraglutide","volume":"29","author":"Bovijn","year":"2019","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.ajem.2024.01.010_bb0295","doi-asserted-by":"crossref","first-page":"367","DOI":"10.18176\/jiaci.0521","article-title":"Delayed hypersensitivity reaction to Liraglutide: a case report","volume":"30","author":"Carvallo","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"10","key":"10.1016\/j.ajem.2024.01.010_bb0300","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1001\/jamadermatol.2019.1893","article-title":"Acute photodistributed exanthematous pustulosis associated with liraglutide treatment","volume":"155","author":"Cogen","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.ajem.2024.01.010_bb0310","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1463-1326.2011.01357.x","article-title":"An overview of once-weekly glucagonlike peptide-1 receptor agonists - available efficacy and safety data and perspectives for the future","volume":"13","author":"Madsbad","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.ajem.2024.01.010_bb0315","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/DAD.0000000000000036","article-title":"Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site","volume":"36","author":"Shan","year":"2014","journal-title":"Am J Dermatopathol"},{"issue":"1","key":"10.1016\/j.ajem.2024.01.010_bb0320","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/cup.12246","article-title":"Eosinophil-rich granulomatous panniculitis caused by exenatide injection","volume":"41","author":"Boysen","year":"2014","journal-title":"J Cutan Pathol"},{"issue":"10","key":"10.1016\/j.ajem.2024.01.010_bb0325","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/DAD.0000000000000243","article-title":"Exenatide-induced eosinophil-rich granulomatous panniculitis: a novel case showing injected microspheres","volume":"37","author":"Andr\u00e9s-Ramos","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.ajem.2024.01.010_bb0330","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ajem.2021.05.006","article-title":"Emergency medicine updates: anaphylaxis","volume":"49","author":"Long","year":"2021","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.ajem.2024.01.010_bb0335","unstructured":"What to know about \u201cOzempic face\u201d. Medical News Today. https:\/\/www.medicalnewstoday.com\/articles\/ozempic-face#prevention"},{"issue":"2","key":"10.1016\/j.ajem.2024.01.010_bb0340","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.ajkd.2013.10.057","article-title":"Acute interstitial nephritis after treatment with liraglutide","volume":"63","author":"Gariani","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.ajem.2024.01.010_bb0345","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1002\/PHAR.1014","article-title":"Liraglutide-induced acute kidney injury","volume":"32","author":"Kaakeh","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.ajem.2024.01.010_bb0350","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(20)30313-2","article-title":"Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials","volume":"8","author":"Mann","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ajem.2024.01.010_bb0355","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2337\/db06-0738","article-title":"Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagonlike peptide 1","volume":"56","author":"de Heer","year":"2007","journal-title":"Diabetes."},{"key":"10.1016\/j.ajem.2024.01.010_bb0360","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1475-2840-11-142","article-title":"Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity","volume":"11","author":"Li","year":"2012","journal-title":"Cardiovasc Diabetol"},{"issue":"10193","key":"10.1016\/j.ajem.2024.01.010_bb0370","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"issue":"19","key":"10.1016\/j.ajem.2024.01.010_bb0375","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajem.2024.01.010_bb0380","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ajem.2024.01.010_bb0385","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db16-1364","article-title":"GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe?","volume":"66","author":"Sim\u00f3","year":"2017","journal-title":"Diabetes."},{"issue":"4","key":"10.1016\/j.ajem.2024.01.010_bb0390","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.ajem.2024.01.010_bb0395","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/dom.13899","article-title":"Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis","volume":"22","author":"Avgerinos","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajem.2024.01.010_bb0400","author":"FDA"},{"key":"10.1016\/j.ajem.2024.01.010_bb0405","author":"GoodRX"},{"key":"10.1016\/j.ajem.2024.01.010_bb0410","author":"GoodRX"},{"key":"10.1016\/j.ajem.2024.01.010_bb0415","author":"GoodRX"},{"key":"10.1016\/j.ajem.2024.01.010_bb0420","author":"Putka"},{"key":"10.1016\/j.ajem.2024.01.010_bb0425","first-page":"147","article-title":"PCDS consensus statement: a strategy for managing the supply shortage of the GLP-1 RAs Ozempic and Trulicity","volume":"24","author":"Beba","year":"2022","journal-title":"Diabetes Prim Care"},{"issue":"3","key":"10.1016\/j.ajem.2024.01.010_bb0430","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2337\/cd23-0023","article-title":"Special report: potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages","volume":"41","author":"Whitley","year":"2023","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.ajem.2024.01.010_bb0435","author":"Bormel"},{"key":"10.1016\/j.ajem.2024.01.010_bb0440","author":"Forbes"},{"issue":"1","key":"10.1016\/j.ajem.2024.01.010_bb0445","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1017\/dmp.2015.137","article-title":"Clinical response, outbreak investigation, and epidemiology of the fungal meningitis epidemic in the United States: systematic review","volume":"10","author":"Abbas","year":"2016","journal-title":"Disaster Med Public Health Prep"},{"key":"10.1016\/j.ajem.2024.01.010_bb0450","author":"Stone"},{"issue":"5","key":"10.1016\/j.ajem.2024.01.010_bb0455","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.japh.2023.06.017","article-title":"Administration errors of compounded semaglutide reported to a poison control center-case series","volume":"63","author":"Lambson","year":"2003","journal-title":"J Am Pharm Assoc"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675724000111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675724000111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:09:11Z","timestamp":1760026151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675724000111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":88,"alternative-id":["S0735675724000111"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2024.01.010","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 agonists: A review for emergency clinicians","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2024.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}